Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2018	Jun. 30, 2018	[1]
Current assets:
Cash and cash equivalents	$ 90.6	$ 110.9
Marketable investment securities	74.8	69.7
Prepaid expenses	12.5	9.4
Inventory	33.3	34.3
Trade accounts receivable	116.6	99.5
Prepaid taxes	3.1
Other receivables	5.9	3.8
Total current assets	336.8	327.6
Property, plant and equipment, net	59.1	43.2
Long-term marketable investment securities	29.9	30.7
Intangibles, net	717.6	455.2
Goodwill	413.2	318.6
Total assets	1,556.6	1,175.3
Current liabilities:
Accounts payable	31.9	26.0
Accrued liabilities	73.7	68.3
Short-term contingent consideration	5.3	5.3
Deferred revenue	2.4	2.6
Total current liabilities	113.3	102.2
Unrecognized tax benefits	24.9	24.9
Other long-term liabilities	6.6	6.3
Contingent consideration	10.4	9.2
Long-term debt	273.3	9.3
Long-term deferred taxes	64.0	57.3
Total liabilities	492.5	209.2
Commitments and contingencies
Stockholders’ equity:
Common stock, 73.2 and 70.6 shares outstanding at December 31, 2018 and June 30, 2018 respectively	0.7	0.7
Additional paid-in capital	1,045.6	915.4
Accumulated other comprehensive loss	(5.0)	(4.1)
Retained earnings	22.9	54.1
Total Myriad Genetics, Inc. stockholders’ equity	1,064.2	966.1
Non-Controlling Interest	(0.1)
Total stockholders' equity	1,064.1	966.1
Total liabilities and stockholders’ equity	$ 1,556.6	$ 1,175.3

[1] Amounts adjusted due to the adoption of Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606). See Note 1 to the financial statements contained in Part I, Item 1 of this report for additional information.